0000000000303639

AUTHOR

Stefan Lethagen

showing 1 related works from this author

A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/Humate -P: history and clinical performance

2008

Patients with von Willebrand disease (VWD) and haemophilia A (HA) lack, to varying degrees, the von Willebrand factor (VWF) and coagulation factor VIII (FVIII) that are critical for normal haemostasis. These conditions in turn make patients prone to uncontrolled bleeding. Historically, patients with severe forms of VWD or HA were crippled before adulthood and their life expectancy was significantly reduced. Over the past decades, specific coagulation factor replacement therapies including Haemate P, have been developed to help patients achieve and maintain normal haemostasis. Haemate P is a human, plasma-derived VWF/FVIII medicinal product, which was first licensed in Germany in 1981 for th…

congenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyHaemophilia AHemophilia AHaemophiliaHaemate P; Humate-P; von Willebrand disease; von Willebrand factor; haemophilia; factor VIIIVon Willebrand factorhemic and lymphatic diseasesInternal medicinevon Willebrand FactormedicineVon Willebrand diseaseHumansDosingDesmopressinHematologybiologybusiness.industryHematologyGeneral Medicinemedicine.diseasevon Willebrand DiseasesCoagulationImmunologybiology.proteinSafetybusinessSettore MED/15 - Malattie del Sanguemedicine.drug
researchProduct